A Randomized, Double-blind, Active-controlled, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Participants who are 19 years old or older.
• Participants who have voluntarily decided to participate in this clinical trial and signed ICF.
Locations
Other Locations
Republic of Korea
Wonju Severance Christian Hospital
RECRUITING
Wŏnju
Contact Information
Primary
Keehyun Ham, Project Leader
hamki@ckdpharm.com
+82-2-2194-0479
Time Frame
Start Date: 2024-10-14
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 324
Treatments
Experimental: Test Group1
Experimental: Test Group2
Active_comparator: CONTROL
Related Therapeutic Areas
Sponsors
Leads: Chong Kun Dang Pharmaceutical